1 Citation (Scopus)

Abstract

We developed and validated a novel hTERT/CMV promoter element-driven gene expression cassette that can robustly enhance cancer-specific gene expression. The following gene expressional elements were located in tandem within the plasmid construct: [hTERT core promoter, cytomegalovirus (CMV) minimized promoter, RU5' sequence, an inserted gene, BGH polyA, hTERT enhancer]; this is hereafter referred to as the hT/Cm-R-hT construct. Using various human cancer cell lines and normal cells, the cancer-specific transcription of the green fluorescent protein (GFP) gene was examined by western blotting and fluorescence microscopy. Cancer-specific gene expression was robustly achieved in the hT/Cm-R-hT plasmid in comparison to the other control hT/Cm-driven construct. Notably, the expression level of GFP observed in the hT/Cm-RhT-driven construct was superior to that of the control plasmid with the conventional CMV promoter in HEK293 cells, which are known to possess higher hTERT activity than normal cells. We next examined the availability of hT/Cm-R-hT in detecting the target GFP expressing cancer cells from human peripheral blood mononuclear cells (PBMCs). The hT/Cm-R-hT plasmid successfully induced cancer-specific gene expression; the robust expression of GFP was observed in target HeLa cancer cells, whereas GFP was not visibly expressed in normal PBMCs. The plasmid allowed for the selective visualization of viable HeLa cancer cells in mixed cell cultures containing up to 10000-fold more PBMCs. These findings indicate that the hT/Cm-R-hT expressional system is a valuable tool for detecting viable cancer cells mixed with normal cells. The current system can therefore be applied to the in vitro detection of cancer cells that are disseminated in the blood and other types of body fluid in vivo. Since the current system can also be applied to other types of vectors, including virus vectors, this approach using the hTERT promoter-based construct is expected to become a valuable tool for enhancing cancerspecific gene expression.

Original languageEnglish
Pages (from-to)1108-1114
Number of pages7
JournalOncology Reports
Volume38
Issue number2
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Neoplasm Genes
Cytomegalovirus
Green Fluorescent Proteins
Gene Expression
Neoplasms
Blood Cells
Plasmids
R Factors
HeLa Cells
Genes
HEK293 Cells
Body Fluids
Fluorescence Microscopy
Cell Culture Techniques
Western Blotting
Viruses
Cell Line

Keywords

  • Cancer
  • Cytomegalovirus promoter
  • Enhancer
  • Gene expression
  • HTERT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{e88595a333804093be717ca382c74e53,
title = "Robust cancer-specific gene expression by a novel cassette with hTERT and CMV promoter elements",
abstract = "We developed and validated a novel hTERT/CMV promoter element-driven gene expression cassette that can robustly enhance cancer-specific gene expression. The following gene expressional elements were located in tandem within the plasmid construct: [hTERT core promoter, cytomegalovirus (CMV) minimized promoter, RU5' sequence, an inserted gene, BGH polyA, hTERT enhancer]; this is hereafter referred to as the hT/Cm-R-hT construct. Using various human cancer cell lines and normal cells, the cancer-specific transcription of the green fluorescent protein (GFP) gene was examined by western blotting and fluorescence microscopy. Cancer-specific gene expression was robustly achieved in the hT/Cm-R-hT plasmid in comparison to the other control hT/Cm-driven construct. Notably, the expression level of GFP observed in the hT/Cm-RhT-driven construct was superior to that of the control plasmid with the conventional CMV promoter in HEK293 cells, which are known to possess higher hTERT activity than normal cells. We next examined the availability of hT/Cm-R-hT in detecting the target GFP expressing cancer cells from human peripheral blood mononuclear cells (PBMCs). The hT/Cm-R-hT plasmid successfully induced cancer-specific gene expression; the robust expression of GFP was observed in target HeLa cancer cells, whereas GFP was not visibly expressed in normal PBMCs. The plasmid allowed for the selective visualization of viable HeLa cancer cells in mixed cell cultures containing up to 10000-fold more PBMCs. These findings indicate that the hT/Cm-R-hT expressional system is a valuable tool for detecting viable cancer cells mixed with normal cells. The current system can therefore be applied to the in vitro detection of cancer cells that are disseminated in the blood and other types of body fluid in vivo. Since the current system can also be applied to other types of vectors, including virus vectors, this approach using the hTERT promoter-based construct is expected to become a valuable tool for enhancing cancerspecific gene expression.",
keywords = "Cancer, Cytomegalovirus promoter, Enhancer, Gene expression, HTERT",
author = "Masakiyo Sakaguchi and Takuya Sadahira and Hideo Ueki and Rie Kinoshita and Hitoshi Murata and Yamamoto, {Ken Ichi} and Junichiro Futami and Yasutomo Nasu and Kazuhiko Ochiai and Hiromi Kumon and Huh, {Nam Ho} and Masami Watanabe",
year = "2017",
month = "8",
day = "1",
doi = "10.3892/or.2017.5710",
language = "English",
volume = "38",
pages = "1108--1114",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Robust cancer-specific gene expression by a novel cassette with hTERT and CMV promoter elements

AU - Sakaguchi, Masakiyo

AU - Sadahira, Takuya

AU - Ueki, Hideo

AU - Kinoshita, Rie

AU - Murata, Hitoshi

AU - Yamamoto, Ken Ichi

AU - Futami, Junichiro

AU - Nasu, Yasutomo

AU - Ochiai, Kazuhiko

AU - Kumon, Hiromi

AU - Huh, Nam Ho

AU - Watanabe, Masami

PY - 2017/8/1

Y1 - 2017/8/1

N2 - We developed and validated a novel hTERT/CMV promoter element-driven gene expression cassette that can robustly enhance cancer-specific gene expression. The following gene expressional elements were located in tandem within the plasmid construct: [hTERT core promoter, cytomegalovirus (CMV) minimized promoter, RU5' sequence, an inserted gene, BGH polyA, hTERT enhancer]; this is hereafter referred to as the hT/Cm-R-hT construct. Using various human cancer cell lines and normal cells, the cancer-specific transcription of the green fluorescent protein (GFP) gene was examined by western blotting and fluorescence microscopy. Cancer-specific gene expression was robustly achieved in the hT/Cm-R-hT plasmid in comparison to the other control hT/Cm-driven construct. Notably, the expression level of GFP observed in the hT/Cm-RhT-driven construct was superior to that of the control plasmid with the conventional CMV promoter in HEK293 cells, which are known to possess higher hTERT activity than normal cells. We next examined the availability of hT/Cm-R-hT in detecting the target GFP expressing cancer cells from human peripheral blood mononuclear cells (PBMCs). The hT/Cm-R-hT plasmid successfully induced cancer-specific gene expression; the robust expression of GFP was observed in target HeLa cancer cells, whereas GFP was not visibly expressed in normal PBMCs. The plasmid allowed for the selective visualization of viable HeLa cancer cells in mixed cell cultures containing up to 10000-fold more PBMCs. These findings indicate that the hT/Cm-R-hT expressional system is a valuable tool for detecting viable cancer cells mixed with normal cells. The current system can therefore be applied to the in vitro detection of cancer cells that are disseminated in the blood and other types of body fluid in vivo. Since the current system can also be applied to other types of vectors, including virus vectors, this approach using the hTERT promoter-based construct is expected to become a valuable tool for enhancing cancerspecific gene expression.

AB - We developed and validated a novel hTERT/CMV promoter element-driven gene expression cassette that can robustly enhance cancer-specific gene expression. The following gene expressional elements were located in tandem within the plasmid construct: [hTERT core promoter, cytomegalovirus (CMV) minimized promoter, RU5' sequence, an inserted gene, BGH polyA, hTERT enhancer]; this is hereafter referred to as the hT/Cm-R-hT construct. Using various human cancer cell lines and normal cells, the cancer-specific transcription of the green fluorescent protein (GFP) gene was examined by western blotting and fluorescence microscopy. Cancer-specific gene expression was robustly achieved in the hT/Cm-R-hT plasmid in comparison to the other control hT/Cm-driven construct. Notably, the expression level of GFP observed in the hT/Cm-RhT-driven construct was superior to that of the control plasmid with the conventional CMV promoter in HEK293 cells, which are known to possess higher hTERT activity than normal cells. We next examined the availability of hT/Cm-R-hT in detecting the target GFP expressing cancer cells from human peripheral blood mononuclear cells (PBMCs). The hT/Cm-R-hT plasmid successfully induced cancer-specific gene expression; the robust expression of GFP was observed in target HeLa cancer cells, whereas GFP was not visibly expressed in normal PBMCs. The plasmid allowed for the selective visualization of viable HeLa cancer cells in mixed cell cultures containing up to 10000-fold more PBMCs. These findings indicate that the hT/Cm-R-hT expressional system is a valuable tool for detecting viable cancer cells mixed with normal cells. The current system can therefore be applied to the in vitro detection of cancer cells that are disseminated in the blood and other types of body fluid in vivo. Since the current system can also be applied to other types of vectors, including virus vectors, this approach using the hTERT promoter-based construct is expected to become a valuable tool for enhancing cancerspecific gene expression.

KW - Cancer

KW - Cytomegalovirus promoter

KW - Enhancer

KW - Gene expression

KW - HTERT

UR - http://www.scopus.com/inward/record.url?scp=85021914632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021914632&partnerID=8YFLogxK

U2 - 10.3892/or.2017.5710

DO - 10.3892/or.2017.5710

M3 - Article

C2 - 28627633

AN - SCOPUS:85021914632

VL - 38

SP - 1108

EP - 1114

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 2

ER -